Marsot Amélie, Imbert Bruce, Alvarez Jean-Claude, Grassin-Delyle Stanislas, Jaquet Isabelle, Lançon Christophe, Simon Nicolas
Service de Pharmacologie Clinique, Hôpital Timone, APHM, Aix Marseille Université, Marseille, France; Equipe d'accueil 3279 Santé Publique et Maladies Chroniques, Aix Marseille Université, Marseille, France.
Alcohol Clin Exp Res. 2014 Feb;38(2):316-21. doi: 10.1111/acer.12235. Epub 2013 Aug 22.
Baclofen is a GABA-B receptor agonist used in the treatment of spasticity. Recently, baclofen is used out of its label to decrease craving of alcoholic patients. Its optimal use in these patients requires further pharmacokinetic information. The objective of this study was to characterize the pharmacokinetics of baclofen in alcohol-dependent patients. Randomized clinical trials are ongoing to evaluate the efficacy for this new indication.
Thirty-seven outpatients (weight: 74.0 kg [42.0 to 104.0]; age: 49 years [31 to 68]) followed in the addictology unit were studied. Total mean dose of 77.9 mg (30 to 240) per day was administered by oral route. Therapeutic drug monitoring allowed the measurement of 139 plasma concentrations. The following covariates were evaluated: demographic data (age, body weight, height, sex), biological data (creatinine, urea, AST, ALT, albumin, PR, VGM, PAL, CDT, GGT), and tobacco consumption (number of cigarettes and Fagerstrom test). Pharmacokinetic analysis was performed by using a nonlinear mixed-effect population model (NONMEM 7.2 software).
Data were modeled with a 1-compartment pharmacokinetic model. The population typical mean (95% confidence interval [95% CI]) values for clearance (CL), apparent volume of distribution (V), and rate constant of absorption (Ka) were 9.9 l/h (9.0 to 11.1), 80.7 l (63.6 to 96.9), and 4.6/h (1.5 to 19.9), respectively. The interindividual variability of CL (95% CI) and V (95% CI), and residual variability (95% CI) were 56.0% (47.9 to 60.7), 68.3% (48.7 to 80.1), and 0.096 mg/l (0.079 to 0.107), respectively.
Baclofen exhibited a linear pharmacokinetics with a proportional relationship from 30 to 240 mg per day, the dose range currently used in alcoholic patients. A wide interpatient variability was observed which could not be explained by the covariates. This high variation of baclofen exposure may explain the lack of response observed for some patients.
巴氯芬是一种用于治疗痉挛的γ-氨基丁酸B(GABA-B)受体激动剂。最近,巴氯芬被超适应症用于减轻酒精依赖患者的酒瘾。在这些患者中其最佳使用方法需要更多的药代动力学信息。本研究的目的是描述巴氯芬在酒精依赖患者中的药代动力学特征。正在进行随机临床试验以评估这一新适应症的疗效。
对成瘾科的37名门诊患者(体重:74.0千克[42.0至104.0];年龄:49岁[31至68])进行研究。每天经口服途径给予的总平均剂量为77.9毫克(30至240)。通过治疗药物监测测定了139个血浆浓度。评估了以下协变量:人口统计学数据(年龄、体重、身高、性别)、生物学数据(肌酐、尿素、谷草转氨酶、谷丙转氨酶、白蛋白、前白蛋白、视黄醇结合蛋白、转铁蛋白、平均红细胞体积、红细胞平均血红蛋白含量、γ-谷氨酰转移酶)以及烟草使用情况(香烟数量和法格斯特龙测试)。使用非线性混合效应群体模型(NONMEM 7.2软件)进行药代动力学分析。
数据采用单室药代动力学模型进行建模。清除率(CL)、表观分布容积(V)和吸收速率常数(Ka)的群体典型均值(95%置信区间[95%CI])分别为9.9升/小时(9.0至11.1)、80.7升(63.6至96.9)和4.6/小时(1.5至19.9)。CL(95%CI)和V(95%CI)的个体间变异性以及残余变异性(95%CI)分别为56.0%(47.9至60.7)、68.3%(48.7至80.1)和0.096毫克/升(0.079至0.107)。
巴氯芬呈现线性药代动力学,在目前酒精依赖患者使用的每天30至240毫克剂量范围内呈比例关系。观察到患者间存在较大变异性,且协变量无法解释这种变异性。巴氯芬暴露的这种高度变异性可能解释了部分患者无反应的现象。